



ORION NUTRACEUTICALS INC. RECEIVES RECEIPT FOR PROSPECTUS AND CONDITIONAL APPROVAL TO LIST SHARES ON CSE, ANNOUNCES CONSULTING AGREEMENTS, AND STOCK OPTION GRANTS

Vancouver, BC, October 5, 2018 – Orion Nutraceuticals Inc. (the 'Company') is pleased to announce that it has filed and obtained a receipt from the British Columbia Securities Commission dated October 2, 2018 for its Final Non-Offering Prospectus ('Prospectus') dated September 27, 2018. A copy of the Prospectus is available on SEDAR under the Company's profile at www.sedar.com. The Company has also received conditional approval from the Canadian Securities Exchange (the 'CSE') for the listing of its common shares on the CSE subject to the completion of customary requirements of the CSE, including the receipt of all required documentation. Once final approval is received, the common shares of the Company will commence trading under the trading symbol: ORI.

Consulting Agreements and Stock Option Grants

The Company also announces that it has entered various consulting agreements (the 'Agreements') with consultants of the Company for providing corporate development and market awareness services. Pursuant to the terms of the Agreements, the Company will grant an aggregate 1,100,000 incentive stock options to purchase the Company's shares at an exercise price of \$0.25 per common share. 600,000 of such options are exercisable for a period of five years from the date of issuance, while 500,000 of such options are exercisable for a period of two years from the date of issuance. The Company will also grant 200,000 options to a director and officer of the Company at an exercise price of \$0.25 per common share for a period of five years from the date of issuance. The effective date of the grants is October 5, 2018. The grant of options will be in accordance with Policies of the CSE and regulatory authorities.

About Orion Nutraceuticals Inc.

Orion Nutraceuticals Inc. (CSE:ORI) The Issuer, through its subsidiary MedicOasis, a Quebec corporation, is an applicant under the ACMPR to become a licensed producer of medical cannabis. The Issuer also has made an investment in a Colombian company that is involved in medical cannabis operations in Colombia.

For more information about Orion Nutraceuticals Inc., visit www.orionnutra.ca

Investor Relations Contact:

Robin Linden

investors@orionnutra.ca

1.604.609.6196

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.